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In modern animal husbandry veterinary medicines are used non therapeutically to 
promote the health and growth of animals. While economical losses due to animal 
sickness have been reduced this practice has also created problems. As it is generally 
known many pharmaceuticals have antibiotic properties and low biodegradability. 
Nowadays their behaviour in the environment is a common topic of discussion and 
research. 
 
In this study, amoxicillin was added into phosphate and ammonium buffer solutions. 
The purpose was to observe how the pharmaceutical is behaving in the presence of 
PO4
3-
 and NH4
+
 ions during time span of approximately 180min. 2% MeOH solutions 
was used as control. 
 
Measurements were done with HPLC. Phenomenex Gemini-NX 5µm C18 110A 
column was used. Mobile phase was 10mM pH 6,1 KH2PO4 and MeCN (95:5). 
Wavelength was set to 227nm and flow rate to 1,5ml/min. 
 
The chromatograms displayed two analyte peaks for each sample. Since no MS was 
performed, AMX could not be identified. During method development phase peak 2 
displayed signs of molecular changes. However, these were not observed in the final 
results, suggesting that no degradation had occurred during the experiment. 
Key words: veterinary medicines, amoxicillin, phosphate ion, ammonium ion, HPLC, 
two peaks, degradation of pharmaceutical 
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Nykyaikaisessa maataloudessa tuotantoeläimiä lääkitään ennaltaehkäisevästi 
tuottavuuden parantamiseksi. Vaikka eläimien sairastumisesta johtuva hävikki on 
vähentynyt, käytäntö voi aiheuttaa myös ongelmia. Kuten on yleisesti tiedossa, monet 
lääkeaineet ovat antibakteerisia ja hajoavat siksi hitaammin luonnossa. Aihe on saanut 
viime vuosina huomiota niin tutkimuksessa kuin mediassakin. 
 
Tässä tutkimuksessa pyrittiin selvittämään onko fosfaatti- ja ammoniumionien 
pitoisuuksilla vaikutusta amoksisilliinin käyttäytymiseen liuoksessa. Työssä 
lääkeainetta lisättiin puskuriliuoksiin, joista sen pitoisuus määritettiin tietyin väliajoin 
HPLC-laitteella n. 180min ajan. Kontrollinäytteenä käytettiin 2% MeOH liuosta. 
Käytettävä kolonni oli Phenomenex Gemini-NX 5µm C18 110A. Eluenttina käytettiin 
isokraattista 10mM pH 6,1 KH2PO4 ja MeCN (95:5). UV-lampun aallonpituus 
säädettiin 227nm ja järjestelmän virtausnopeus 1,5ml/min. 
 
Lopullisissa mittaustuloksissa esiintyi mahdollisesti kaksi eri ainetta. Näitä ei voitu 
tunnistaa, sillä työssä ei käytetty MS-laitetta. Menetelmää kehittäessä toinen aineista 
näytti hajoavan, mutta vastaavia havaintoja ei kuitenkaan tehty varsinaisissa 
mittauksissa. Vaikka tunnistamattomat aineet eivät pysyneet kokeen aikana täysin 
muuttumattomina, tulokset eivät todistettavasti viitanneet lääkeaineen suoranaiseen 
hajoamiseen. 
Avainsanat: tuotantoeläinten lääkkeet, amoksisilliini, fosfaatti-ioni, ammoniumioni, 
HPLC, lääkeaineen hajoaminen 
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ABBREVIATIONS AND TERMS 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
λ  Wavelength (nm) 
ADP  Amoxicillin diketopiperazine-2´, 5´ (Lamm et al., 2009) 
AMX  Amoxicillin (Lamm et al., 2009) 
Apeak  Peak area 
Are  Relative area 
C2H7NO2  Ammonium acetate 
CO2  Carbon dioxide 
H
+
  Hydrogen ion 
H2O  Water 
H3O
+
  Hydronium ion 
HPLC  High performance liquid chromatography 
k  Slope 
KH2PO4  Potassium dihydrogen phosphate 
LC  Liquid chromatography 
LC/MS  Liquid chromatography mass spectrometry 
M  Molarity (mol/l) 
MeOH  Methanol 
MeCN  Acetonitrile 
MS  Mass spectrometry 
NaH2PO4  Sodium dihydrogen phosphate 
Na3PO4  Trisodium phosphate 
NaOH  Sodium hydroxide 
NH3  Ammonia 
NH4
+
  Ammonium ion 
OH
-
  Hydroxide ion 
OTC  Oxytetracycline (Chemical Book, 2010) 
p  Pressure (bar) 
pmax  Maximum pressure (bar) 
PO4
3-
  Phosphate ion 
ppm  Parts per million (mg/l) 
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R
2
  Correlation 
RT  Retention time (min) 
SMZ  Sulphamethoxazole (Chemspider, 2014, Sulphamethoxazole) 
SPE  Solid phase extraction 
T  Temperature (°C) 
t  time (min) 
TYL  Tylosin 
UHP  Ultra high purified 
UV  Ultraviolet 
V  Volume (ml) 
Vinjection  Injection volume (µl) 
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1 INTRODUCTION 
 
Usage of veterinary medicines in modern agriculture is common thorough the whole 
world. In animal husbandry pharmaceuticals and hormones are non therapeutically 
given to livestock in order to improve their health and growth (Animal Health Institute, 
2014; Martin et al., 2010; YLE 1, 2013; The Wall Street Journal, 2013). 
 
A study published in Journal of Antimicrobial Chemotherapy shows that in year 2007 
18-188mg of veterinary antibacterial agents were sold per a kilogram of meat (swine, 
cattle and poultry) produced within 10 selected European countries (Grave et al., 2010). 
Netherlands and France had the highest amount, while Norway, Sweden and Finland 
had the lowest. Out of the EU countries Sweden had the lowest value (~25mg/kg). 
 
While the modern practice has prevented disease and thus minimised losses (YLE 1, 
2013), specialist of different fields criticise the carefree attitude of using livestock 
medication for non therapeutic purposes (prevention, growth improvement). Elstrøm 
from the Norwegian Public Health Institute stated that ”there is a direct link between the 
use of antibiotics in livestock and resistant bacteria in humans” (EurActiv, 2014). 
Continuing with the current practices could potentially lead to formation of antibiotic 
resistant super bacteria (Mackie, 2011; RT, 2014). 
 
The non metabolised pharmaceuticals are excreted by the animals and can be found in 
trace amounts from the faeces and urine. Eventually these will end up into the soil and 
natural water bodies. 
 
There is reason to believe that these compounds have certain persistence in the 
environment. Biological degradation may occur slowly due to the natural antibiotic 
properties of certain compounds. Furthermore, as the molecules are complex, unknown 
chemical reactions between different compounds may occur. This way new, potentially 
more hazardous substances can be formed (YLE 2, 2013). 
 
While the final fate of these substances in the environment remains unclear (YLE 2, 
2013), it is heavily researched on nowadays. During recent years the issue has been 
getting more attention in the media, raising public awareness (YLE 3, 2013). 
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2 BACKGROUND 
 
The basis for this thesis work is laid on two scientific papers. These were Factors 
affecting the degradation of amoxicillin in composting toilet by Kakimoto and 
Funamizu (2006), and Degradation of veterinary medicines in composting process of 
livestock manure by Ishiduka (2013). 
 
Kakimoto and Funamizu had discovered that the degradation of amoxicillin had a 
relation to the concentration of phosphate, ammonium and hydroxyl ions in composting 
environment. It was concluded that these were factors controlling the degradation 
process. 
 
In her work Ishiduka noticed that degradation of the selected veterinary medicines 
(including amoxicillin) occurred regardless of biological activity. She concluded that 
the cause of degradation was chemical reactions. 
 
During my internship period in Japan in spring 2013, I applied Kakimoto’s and 
Funamizu’s method (although modified) on three of Ishiduka’s pharmaceuticals (SMZ, 
OTC and TYL). The aim of my work was to find out if phosphate and ammonium ions 
had an effect on the degradation rate. 
 
While in Japan, I discussed with Kakimoto, Funamizu and Ishiduka in person. In our 
conversation I gained a lot of practical information about the setup of the experiments 
itself, knowledge that cannot be found from books or Internet. This was very beneficial 
regarding my work. After several trials, I was able to conduct the experiment. Sample 
preparation was done by using a SPE method. Analysis was carried out by using 
LC/MS. 
 
The results failed to show proper degradation lines for the pharmaceuticals as the level 
of detected pharmaceuticals was varying unnaturally. While there had been some issues 
with the LC/MS in the past, this was not the probable cause.  Mistakes in the SPE 
process were suspected. 
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Regardless of this, I presented my findings in a seminar at the end of my internship 
period. After my presentation I received several comments. A Ph.D. candidate in my 
laboratory pointed out that it would have been wiser to first see whether I could repeat 
Kakimoto’s and Funamizu’s experiment with amoxicillin before applying the method 
for any other pharmaceuticals. Realized that this was elementary, I concluded that any 
further work should focus on that. 
 
After discussing the continuation of the research with my teachers, I got my Bachelor’s 
thesis topic accepted. In January 2014 I started working in the laboratories at Tampere 
University of Applied Sciences. 
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3 THEORY 
 
 
3.1 Amoxicillin 
 
Amoxicillin (C16H19N3O5S; Figure 1) is a semi synthetic antibiotic substance belonging 
to the penicillin group (Chemspider, 2014, Amoxicillin; Crosta, 2012). It is used in the 
treatment of several bacterial infections, including “infections of the ears, nose, throat, 
urinary tract, and skin” (MedlinePlus, 2010). More serious microbial infections, such as 
the ones caused by E. coli and salmonella can also be treated with amoxicillin (Drugs, 
2014). 
 
While the form, regulations, practice and dosage varies, amoxicillin is therapeutically 
used to treat both human and animal disease. 
 
 
 
Figure 1. Amoxicillin molecule (ChemSpider, 2014, Amoxicillin). 
 
 
3.2 Buffers 
 
The pH of any solution is determined by the ratio between H3O
+
 and OH
-
 ions (Lewis et 
al., 2001; pp. 286-287).  This ratio can be easily changed by adding acid or base, thus 
moving the equilibrium. 
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Solutions with the ability to resist this change are called buffers. They contain “a weak 
base and one of its salts, or a weak acid and one its salts” (Lewis et al., 2001; p. 298). 
These solutions have components capable of binding H
+
 ions and changing OH
-
 ions 
into water molecules (Clark, 2002, buffer solutions). Naturally, this ability is limited, 
and is determined by the capacity of the buffer (Lewis et al., 2001; p. 300). 
 
Buffers are naturally present in soil and water bodies, but also in living cells and body 
liquids such as blood, where changes in pH would be catastrophic (terracult; Lewis et 
al., 2001, p. 297). 
 
 
3.3 Chromatography 
 
 
3.3.1 Principle 
 
Chromatography is a method for separating different components from mixtures (Clark, 
2007, thin layer chromatography). While there are several types of chromatographic 
applications in use, the operating principle is always the same (Clark, 2007, thin layer 
chromatography). 
 
Basically a chromatograph requires two things to function: a mobile phase and a 
stationary phase. The purpose of the mobile phase is to transfer the sample through the 
stationary phase. The function of the stationary phase is to separate the analytes (target 
compounds) from each other utilizing the differences in their chemical properties 
(Clark, 2007, thin layer chromatography). 
 
 
3.3.2 HPLC 
 
High performance liquid chromatography is a sophisticated application of liquid 
chromatography. It utilises high pressure (up to 400bar) making the separation process 
much faster than in simple chromatographic applications using only gravitational force 
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(Clark, 2007, high performance liquid chromatography - HPLC). Figure 2 shows a 
simplified design of a HPLC unit. 
 
 
 
Figure2. An illustration of HPLC unit. 
 
 
Eluent is the liquid functioning as the mobile phase in LC. Depending on the method, it 
can be either isocratic or gradient. The composition of an isocratic eluent remains 
constant during the run, while gradient changes steadily (Types of HPLC). This can be 
beneficial, if there is more than one target compound is to be measured. 
 
The column used in HPLC is a cylindrical metallic tube with silica surface on the inside 
(Clark, 2007, thin layer chromatography). This functions as the stationary phase in LC, 
separating the analytes from the eluent. The separation process is very delicate and 
requires careful control of conditions (explained further on). 
 
 
Separation process 
 
Based on the nature of the stationary phase and separation process, the majority of all 
liquid column chromatography applications can be classified into two categories: size 
exclusion chromatography and ion exchange chromatography (Types of HPLC). The 
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latter one is further divided into normal phase and reversed phase chromatography 
(Types of HPLC). 
 
 
Size exclusion chromatography 
 
“In size exclusion chromatography the column is filled with material having precisely 
controlled pore sizes” (Types of HPLC). The pores function as filters, controlling the 
size of molecules that can travel through them. Larger molecules are rapidly washed 
through the column, while the smaller travel through the pores, thus taking longer time 
to reach the end of the column (Types of HPLC). 
 
 
Ion exchange chromatography 
 
The separation process in ion exchange chromatography is based on the opposite 
charges between the stationary phase and sample ions (Types of HPLC). “The stronger 
the charge on the sample, the stronger it will be attracted to the ionic surface and thus, 
the longer it will take to elute” (Types of HPLC). 
 
In normal phase chromatography the stationary phase is polar (e.g. silica) and the 
mobile phase non polar. This retains the polar compounds inside the stationary phase, 
while the non polar ones will stay in the mobile phase and travel through faster (Clark, 
2007, high performance liquid chromatography - HPLC). 
 
Reversed phase chromatography is the exact opposite of normal phase. The stationary 
phase is non polar (silica modified with long hydrocarbon chains) and the mobile phase 
polar (Clark, 2007, high performance liquid chromatography – HPLC). Reversed phase 
chromatography uses either C8 or C18-columns as stationary phase (Clark, 2007, high 
performance liquid chromatography – HPLC). 
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Retention time 
 
The time it takes for a compound to pass through the column and reach the detector is 
referred to as retention time. RT for a particular compound will depend on column 
temperature, flow rate (affects directly the pressure), how well it is dissolving in the 
eluent and how much it is reacting with the surface of the column (Clark, 2007, thin 
layer chromatography).  If these conditions stay exactly the same, theoretically speaking 
no variations in RT for a particular compound should occur. 
 
 
Detector 
 
After the separation process, the analytes reach the UV detector (Figure 2). UV 
wavelength radiation (40-400nm) is emitted from the lamp and directed to travel 
through the eluent carrying the analytes (Deman, 2011; Figure 3). The amount of 
radiation absorbed will be measured, and the data is sent to the computer. 
 
 
 
Figure 3. A picture illustrating how the UV radiation is directed towards the detector 
(Clark, 2007, high performance liquid chromatography - HPLC). 
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Integration of chromatogram 
 
The output of the detector is referred to as chromatogram (Figure 4) (Chromatography - 
The Chromatogram), which is basically the baseline with peaks for the detected 
compounds. Based on the setting of the computer, these peaks are integrated and yield 
an area value. 
 
 
 
Figure 4. Simplified chromatogram peaks (Clark, 2007, high performance liquid 
chromatography - HPLC). 
 
 
“According to the Beer-Lambert Law, absorbance is proportional to concentration -- as 
long as the solutions are dilute“ (Clark, 2007, using UV-visible absorption spectra). In 
other words, higher the area of the peak means higher concentration of analytes (Clark, 
2007, high performance liquid chromatography - HPLC). 
16 (48) 
 
 
4 OBJECTIVE 
 
The objective of this study was to find out whether PO4
3-
 and NH4
+
 ions have an effect 
on the degradation of amoxicillin at constant pH conditions. This was done by 
performing a similar experiment to Kakimoto’s and Funamizu’s one. 
 
There were four stages in the work: 
 
The first stage was to plan and develop an experiment where PO4
3-
 and NH4
+
 ions are 
present in a solution at constant pH conditions. After this it was necessary to find a 
method capable of measuring the pharmaceutical to be studied from these solutions. 
This was applied to the selected pharmaceutical (AMX). Based on the results 
conclusions were made. 
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5 METHOD 
 
The principle of the new method was to spike the pharmaceutical in a solution and make 
consecutive injections in HPLC. 
 
 
5.1 Stock solution 
 
Stock solution for amoxicillin was prepares by weighting 11.5 mg of amoxicillin 
trihydrate (~10mg of pure amoxicillin) in a weighting vessel. The pharmaceutical was 
washed from the weighting vessel into a 10ml volumetric flask with MeOH. 500µl of 
UHP water was added by using an automatic pipette. After this the flask was filled up to 
the line with MeOH. The flask was then sealed and shaken until amoxicillin was 
completely dissolved. 
 
The final solution had 1000ppm of pure amoxicillin dissolved in 95% MeOH. The 
solution was poured into a 10ml brown glass laboratory bottle. The bottle was sealed, 
covered with aluminium foil and stored in freezer (-17°C). 
 
Methanol was used as the solvent because of two reasons. One:  amoxicillin is reported 
to be soluble in methanol (see text further on). Two: MeOH solution can be stored in a 
freezer in liquid form and is easy to spike. 
 
As it is commonly known, absolute methanol is very hydrophilic and evaporates easily. 
In order to reduce changes in volume during storage, MeOH used was diluted from 
100% to 95%. Storing the bottle in freezer further reduced this effect. While the 
freezing point of the mixture is higher than that of absolute methanol, this did not matter 
since very low temperature was not used (-17°C). 
 
When preparing the sample it was noticed that the trihydrate form was dissolving poorly 
in 95% MeOH. The reason for this remained unclear, since amoxicillin is known to be 
dissolving in water and methanol (Merck Index, 2001, p. 96). Other antiobiotics, such 
as SMZ, OTC and TYL dissolve in MeOH very quickly. 
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As the prepared stock solution was very concentrated (1000ppm), it was possible to use 
a low spiking volume (200µl per 10ml) and still have a relatively high concentration of 
pharmaceuticals in the sample (20ppm). Higher concentration in the sample made 
detection easier. 
 
 
5.2 Diluents 
 
The diluents were prepared in the described manner. 
 
 
5.2.1 Methanol solution 
 
The 2% MeOH solution was prepared by filling a 10ml volumetric flask with UHP 
water almost until the line. 200µl of MeOH was added by using an automatic pipette. 
After this the flask was filled until the line with UHP water, sealed and shaken. 
 
 
5.2.2 Phosphate buffer 
 
50ml of 200mM Na3PO4 solution and 50ml 200mM NaH2PO4 solution were prepared. 
NaH2PO4 solution was emptied into a beaker. While constantly stirring and measuring 
the pH, Na3PO4 solution was added with pasteur pipette until pH 8,5 was reached. 
 
 
5.2.3 Ammonium buffer 
 
50ml of 200mM C2H7NO2 solution and 50ml 200mM NH3 solution were prepared. 
C2H7NO2 solution was emptied into a beaker. While constantly stirring and measuring 
the pH, NH3 solution was added with pasteur pipette until pH 8,5 was reached. 
 
The ammonia calculation was made by using a table found from Internet (Chemistry 
Archive). Due to volatilisation of ammonia in basic conditions (Richard, 1996), the 
readymade buffer solution was stored in fridge. 
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5.3 UV spectrum 
 
UV spectrum was determined for AMX by using UV/VIS spectrometer (Figure 5). The 
values were measured from 1% MeOH solutions with pharmaceutical concentration of 
10ppm. Total of three measurements were done. 1% MeOH solution was used as 
control. 
 
 
 
Figure 5. PerkinElmer instruments UV/VIS Spectrometer unit. 
 
 
5.4 Sample preparation 
 
Each sample solution containing pharmaceutical was prepared three minutes before the 
injection in order to give accurate result for the initial (0min) measurement. 
 
A 10ml volumetric flask was filled almost until the line with diluent. 200µl of 
pharmaceutical stock solution was spiked by using an automatic pipette. The flask was 
filled until the line with diluent, sealed and shaken for one minute. 
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After this, the solution was poured into a small beaker. Some of the solution was 
transferred into a syringe (1-2ml). Air was removed by turning the syringe vertically up 
and tapping the side lightly so that the air bubble moved to the surface. Some solution 
was pressed out from the solution, at the same time removing the air bubble. 
 
Next a syringe filter was placed to the end of the syringe. The solution was lightly 
pressed through the filter into a 2ml screw cap via. The vial was sealed and placed on 
the autosampler rack, ready to be automatically injected. 
 
 
5.5 HPLC method 
 
For this work, an existing HPLC method for amoxicillin was modified (Lunn, 2000, p. 
385) (see method settings).  Analysis was carried out by using Agilent HPLC 1100 
Series unit (Figure 7). The separation process was reversed phase chromatography. A 
C18 column was used with guard column attached (Figure 6). 
 
 
 
Figure 6. Phenomenex Gemini-NX 5µm C18 110A column with a guard column 
attached. 
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Figure 7. Agilent HPLC 1100 Series unit. 
 
 
5.5.1 Eluent 
 
Eluent A was made by preparing 10mM solution of KH2PO4 solution and setting the pH 
to 6,1 with NaOH (Table 1). The solution was filtered by using a vacuum filtration unit 
in order to reach HPLC grade (Figure 8). MeCN was used as eluent B. 
 
Table 1. Mobile phase used in amoxicillin measurements (isocratic). 
  A B 
Eluent 10mM KH2PO4 pH 6.1 (NaOH) MeCN 
v/v (%) 95 5 
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Figure 8. Vacuum filtration unit used for preparing eluent A. 
 
 
5.5.2 Experimental conditions 
 
HPLC method settings can be seen from table 2. 
 
Table 2. Method settings for HPLC. *) Changed from the original method (Lunn, 2000, 
V2, p. 385). 
Column Phenomenex Gemini-NX 5µm C18 110A * 
V (injection) 20µl 
Flow rate 1.5ml/min * 
T (column)  Ambient (~20°C) 
t 15min or 17min 
p (max) 250bar 
23 (48) 
 
 
5.5.3 Integration settings 
 
The integration settings of the HPLC unit are presented in table 3. The limits were set 
quite low on purpose in order to get all peaks integrated. 
 
Table 3. Integration settings for chromatogram analysis. 
Slope sensitivity 5 
Min. peak width 0.05min 
Min. peak height 0.1mAU 
Min. peak area 1 
 
 
5.6 Reporting and data processing 
 
The used HPLC method reported the results of the measurements in PDF and TXT 
format. Chromatograms were screen captured from the PDF files. Raw data from TXT 
files was used to produce the figures.  MO Excel was used for data processing. 
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6 RESULTS 
 
The results of the experiments are presented in this chapter. 
 
 
6.1 UV spectrum 
 
The UV spectrum for AMX can be seen from figure 9. 
 
 
 
Figure 9. UV spectrum of amoxicillin. 
 
 
According to the measurements amoxicillin reaches maximum absorbance at 
approximately 228nm. Wavelength of 227nm was used in the HPLC measurements. 
This is very close to the previously reported values (de Abreu et al., 2003; Drug Future, 
2013; Jang Lee et al., 2013). 
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6.2 HPLC 
 
The results for the HPLC measurements are presented here. Due to limitations in using 
of analytical equipment, some measurements were done with fewer injections than 
others. In order to compare the figures better, linear lines estimating the probable 
development of the scatter plots were drawn by using k value. 
 
 
6.2.1 Chromatograms 
 
Every time a new measurement begun the produced chromatogram received some 
disturbance. This originated from the injection itself, as well as UV absorbance of 
solution the analytes were dissolved in (diluent).  This part of the chromatogram was 
referred to as noise, and was excluded from the data analysis. 
 
Figures 10, 13 and 16 are examples of chromatograms from injections containing only 
the sample diluent without any pharmaceuticals. This information made it possible to 
estimate the effect the diluents used had on the AMX measurements, thus improving the 
accuracy of the method. 
 
The sample injection was compared against the chromatogram produced by the diluent. 
While these could not be overlapped by the program, it still made it possible to identify 
the peaks originating from the spiked pharmaceutical. This is true, since (as far as it is 
known) only one new substance has been introduced. 
 
The chromatogram in figure 10 is produced by 2% MeOH diluent injection. While the 
baseline is not fully stabilised, the peak produced by diluent is visible. 
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Figure 10. 2% MeOH injection (SIG1026945). 
 
 
Figure 11 demonstrates the chromatogram in produced by 2% MeOH+20ppm AMX 
injection at 0min. Peak 1 is sharp and high, staying nearly constant during the 
measurements. Peak 2 on the other hand, is short and wide. Towards the end, the peak is 
splitting (Figure 12). 
 
 
 
Figure 11. 2% MeOH+20ppm AMX  injection (0min) (SIG1026946). 
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Figure 12. 2% MeOH+20ppm AMX  injection (195min) (SIG1026959). 
 
 
The chromatogram in figure 13 represents 200mM pH 8,5 phosphate buffer+2% MeOH 
injection. Baseline is good and diluent peaks clearly visible. 
 
 
 
Figure 13. 200mM pH 8,5 phosphate buffer+2% MeOH injection (SIG1026965). 
 
 
Figure 14 demonstrates the chromatogram produced by 200mM pH 8,5 phosphate 
buffer+2% MeOH+20ppm AMX injection at 0min. Again, peak 1 is very sharp, high 
and stays constant. Peak 2 is fronting in the beginning, but seems to turn vertical and 
sharpen later on (Figure 15). 
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Figure 14. 200mM pH 8,5 phosphate buffer+2% MeOH+20ppm AMX injection (0min) 
(SIG1026966). 
 
 
 
Figure 15. 200mM pH 8,5 phosphate buffer+2% MeOH+20ppm AMX injection 
(187min) (SIG1026977). 
 
 
Next is the chromatogram for 200mM pH 8,5 ammonium buffer+2% MeOH injection 
(Figure 16). Baseline is very good and diluent peaks clearly visible. 
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Figure 16. 200mM pH 8,5 ammonium buffer+2% MeOH injection (SIG1027004). 
 
 
Figure 17 demonstrates the chromatogram produced by 200mM pH 8,5 ammonium 
buffer+2% MeOH+20ppm AMX injection at 0min. Surprisingly, peak 1 is clearly 
shorter than in other treatments. The peak stays sharp and nearly constant. Peak 2 
resembles an equilateral triangle, and seems to be slightly broadening to the right hand 
side (Figure 18). 
 
 
 
Figure 17. 200mM pH 8,5 ammonium buffer+2% MeOH+20ppm AMX injection 
(0min) (SIG1027005). 
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Figure 18. 200mM pH 8,5 ammonium buffer+2% MeOH+20ppm AMX injection 
(180min) (SIG1027017). 
 
 
As can be seen from figures 10, 13 and 16, the diluent chromatograms have almost no 
peaks at RT>1,5min. Same peaks can be found from sample chromatograms. 
  
Figures 11, 12, 14, 15, 17 and 18 represent the sample injections. As can be seen from 
the chromatograms, aside from the diluent, two peaks were detected. However, the way 
these are divided and situated (RT, area and shape) is different in each. The peaks were 
labelled simply as peak 1 and peak 2, based on lowest RT. Regardless of their naming, 
peak x (1 or 2) is not necessarily the same compound in each treatment. The name 
simply indicates the order in which they were detected. 
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6.2.2 Retention time 
 
The following scatter plots (Figures 19, 20 and 21) represent RT of the peaks detected 
from consecutive injections of diluent+AMX. 
 
 
 
Figure 19. RT of peak 1&2 in 2% MeOH solution. 
 
 
Figure 19 shows that in control treatment RTpeak1 is ~1,8min and remains practically 
constant (k=-0,001). While RTpeak2 is ~7,4, it does not stay constant. 
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Figure 20. RT of peak 1&2 in 200mM pH 8,5 phosphate buffer + 2%MeOH  solution. 
 
 
As figure 20 represents, in the phosphate buffer treatment both peak 1 and peak 2 have 
stable RT (kpeak1=-9E-05, kpeak2=-0,0016). RTpeak1 is 2min and RTpeak2 ~10min. 
 
 
 
Figure 21. RT of peak 1&2 in 200mM pH 8,5 ammonium buffer+2% MeOH solution. 
 
 
Figure 21 displays that in ammonium buffer treatment RTpeak1 remains constant at 
~2min (k =0,0004). While RTpeak2 is ~8,6min, it does not stay stable. 
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6.2.3 Peak area 
 
The following scatter plots (Figures 22, 23 and 24) represent the area (proportional to 
amount, see theory) of the peaks detected from consecutive injections of diluent+AMX. 
 
 
 
Figure 22. Area of peak 1&2 in 2% MeOH solution. 
 
 
As can be seen from figure 22, the peaks were clearly divided in terms of area. Peak 1 
has an area of ~400 at 0min, and seems to be slightly decreasing (k =-0,021). Area of 
peak 2 starts at ~125 and is increasing (k=0,0701). Towards the end, the peak starts 
splitting and got integrated as two separate ones (Figure 12). Since this had not occurred 
in the other chromatograms, the measurement was excluded. Atotal (Apeak1 + Apeak2) stays 
nearly constant. 
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Figure 23. Area of peak 1&2 in 200mM pH 8,5 phosphate buffer+ 2% MeOH solution. 
 
 
In figure 23, Apeak1 and Apeak2 are practically the same at 0min. Apeak1 is decreasing (k=-
0.0726) while Apeak2 is increasing (k =0.0611). Atotal stays constant. 
 
 
 
Figure 24. Area of peak 1&2 in 200mM pH 8,5 ammonium buffer+2% MeOH solution. 
 
 
In figure 24, Apeak1 is ~100 at 0min and seems to be slightly decreasing (k =-0,0295). 
Apeak2~340 at 0min and is rapidly increasing (k=0,2683). Atotal is increasing, but gets 
stabilised at ~500. 
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7 DISCUSSION 
 
 
7.1 Separate peaks 
 
As the chromatograms display, every sample injection produced two peaks. This 
suggests one of two things. 
 
Either there are two compounds present in each sample. While one of these might have 
been AMX, the other one remains unknown. Since no MS was performed, it was not 
possible to verify that AMX was detected in its unchanged form, let alone to identify 
the other compound. In this case, the phenomenon could be explained by impurities, 
contamination or degradation. 
 
The other possibility is that for some reason AMX appears as two peaks in the 
chromatograms. This could be due to partial ionisation of the analyte. 
 
 
7.1.1 Impurities 
 
It is possible that one of the peaks represents AMX and the other impurities originating 
from the manufactured trihydrate form. In Amoxicillin Summary Validation Report 
(2013) 11 impurities were detected and identified from amoxicillin trihydrate. Are was 
varying per impurity (>12%) but it was surprisingly large when compared to AMX (Are 
~46%). 
 
As the figures 22, 23 and 24 show, Are of peak 1 and peak 2 varied between different 
treatments. In 200mM pH 8,5 phosphate buffer+2%MeOH+AMX solution peak 1 and 
peak 2 have practically equal area at 0min (Figure 23). This suggests that impurities are 
not the cause for two peaks to appear. 
 
One way to reduce the amount of impurities would be to use SPE in the sample 
preparation. While this increases the workload of the method it should reduce the noise 
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in the chromatogram and so improve accuracy. However, the usage of automated SPE 
system is recommended, since the manual method carries higher risk of human error. 
 
 
7.1.2 Contamination 
 
Considering the simplicity of sample preparation procedure and the used working 
practices, contamination seems a very unlikely cause for separate peaks to appear in the 
chromatogram. 
 
 
7.1.3 Degradation products 
 
On the other hand, there is a possibility that the separate peaks originate from 
degradation products of AMX. One pathway of amoxicillin degradation in an aqueous 
medium is transformation into AMX-penicilloic acid, and then into ADP (Lamm et al., 
2009). ADP is further divided into two isomers (Lamm et al., 2009). Both AMX and 
ADP have similar UV spectrum, meaning that if these were present in the same sample, 
both would detected (Lamm et al., 2009). However, in order to verify this MS is 
necessary. 
 
 
7.1.4 Partial ionisation 
 
Another explanation is that the peaks represent the same compound in ionised and non 
ionised form. As it is commonly known, ionisation of analyte in the mobile phase can 
lead to peak splitting (Basniwal, Jain, 2013). When the ionisation time is considerably 
longer than the retention time for the compound, it is possible that two separate peaks 
will appear (Dolan, 2013). In reverse phase chromatography, the first peak represents 
the ionised part and the second the non ionised part of the compound. 
 
According to Dolan (2013) it is possible to affect the way the molecule is behaving 
inside the column by changing the pH of the mobile phase. More acidic eluent forces 
the analytes to stay in their non ionised (also non polar) form and thus retain longer in 
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revered phase separation (Dolan, 2013; Basniwal and Jain, 2013; Nägele and Moritz, 
2005). More alkaline eluent increases ionisation and decreases interaction with the 
column. 
 
The matter could be verified by trying mobile phase of different pH and see how this 
affects the chromatograms. If more acidic eluent produces a single peak for the analyte, 
the cause for peak separation was partial ionisation. Trying this is out is encouraged by 
other HPLC methods using a more acidic (pH=4,8/5,0) phosphate buffer as mobile 
phase (de Abreu et al., 2003; Phenomenex, 2014; Rao et al., 2011). 
 
 
7.2 Peak shape distortions 
 
Peak 1 did not show signs of distortions in any of the treatments. In all cases, the peak 
shape was ideal (Bhanot, 2014). This suggested that the experimental conditions were 
optimal for this compound. 
 
Peak 2, on the other hand, behaved very differently in each treatment. Phosphate buffer 
had the least distortion out of the three treatments. Ammonium buffer had some, but the 
worst distortions were found in control. The mobile phase stayed practically the same, 
as did the experimental conditions. 
 
The distortion can be due to incompatibility of the unionized form of amoxicillin (peak 
2) with the current mobile phase. Change in eluent pH is not likely, as peak 1 had not 
been affected. Change in column temperature is as unlikely for the same reason. 
 
Peak shape distortions may have had some effect on the integration process and the way 
RT is determined. If the tip of a peak is split, it gets integrated as two separate peaks. 
On the other hand, the middle point of a broadening peak is moving horizontally. This 
directly affects RT, but still fails to fully explain the quite strong fluctuations of RTpeak2. 
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7.3 Travelling peaks 
 
Another interesting phenomenon is the travelling peak 2 in control and ammonium 
buffer (Figures 19 and 21). RT is decreasing in the first one and increasing in the second 
one. The cause for the phenomenon is unknown. Normally this suggests changes in the 
measurement conditions (eluent and column) but this is not the case since RTpeak1 
remains stable. 
 
There is possibly is a link between RT fluctuations and shape distortions of peak 2. This 
can be noticed by comparing shape of peak 2 to the corresponding RT scatter plots. 
RTpeak2 in phosphate buffer was stable but also had the least distortions. 
 
One possible cause is change in diluents pH. As control was prepared on 2% MeOH 
solution, there was no buffering capacity. Gradual absorption of CO2 from air made the 
solution slightly acidic. Volatilisation of ammonia may have caused something similar 
in ammonium buffer. 
 
Escape of ammonia cannot be prevented, as the solution pH is one of the factors 
controlling its volatilisation rate (Richard, 1996). The vial had been sealed, but when 
injection was performed, the needle punctured the cap, thus allowing some gases to 
leave the vial. 
 
In the case of control, pH could be set to pH 8,5 with NaOH. In order to get some 
buffering capacity, a weak buffer (5-10mM) could be used. 
 
 
7.4 Peak area 
 
As figure 24 displays, Atotal of peak 1&2 was increasing in ammonium buffer due to 
rapid increase in Apeak2. The cause for this is unknown. 
 
Increase in Apeak indicates increase in the amount of analyte. This is naturally 
impossible, so there must be another reason for this phenomenon. One possible 
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explanation is that the volatilisation of ammonia disturbed the separation process in the 
column, thus affecting the results. 
 
Normally Atotal is not a good indicator of degradation, since the degradation products of 
the original compound will absorb some UV radiation. Therefore concluding remarks 
were not done based on Atotal values. 
 
 
7.5 Degradation 
 
As the data presented too many uncertainties, it was not possible to observe degradation 
of the detected compound(s). While some molecular changes might have occurred, 
these could not be identified due to the shape distortions and travelling peaks in the case 
of control and ammonium buffer. 
 
It has been reported that “ionic strength is one of the important factors responsible for 
amoxicillin degradation” in alkaline solutions (Kakimoto and Funamizu, 2006; Rao et 
al., 2011). This had not been controlled in this experiment, which could be one of the 
reasons why no degradation was observed. 
 
Another major issue is that MeOH might have been unsuitable to be used as a solvent 
for the stock solution of AMX. It is possible that AMX had started to degrade in the 
95% MeOH solution during storage. Rao et al. (2011) states that “degradation of 
amoxicillin (sodium salt) at higher concentration became faster in the presence of ... 
alcohols”. While AMX used in this experiment was trihydrate form, it still might have 
behaved in a similar manner in the presence of MeOH. 
 
Appendix A displays an interesting phenomenon, where peak 2 was changing into 
another compound in the phosphate and ammonium buffers. This had occurred during 
method development. While this could not be reproduced in the actual experiment, it 
was an important observation. 
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8 CONCLUSION 
 
In HPLC measurements two analyte peaks were detected per every injection. One of 
these could have been AMX and the other a degradation product. However, as no MS 
was performed, it was not possible to identify the compound(s). 
 
Separate peaks might have been caused by partial ionisation of the analyte. On the other 
hand, it could be that AMX had started to change in the 95% MeOH stock solution, 
therefore having some degradation products already before spiking. This matter requires 
confirmation. 
  
While peak 2 displayed molecular changes in phosphate and ammonium buffers during 
method development, this phenomenon could not be reproduced in the experiments. 
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9 POSSIBILITIES FOR FUTURE WORK 
 
The experiments left several issues open. 
 
Firstly, it would be interesting to know how more acidic eluent would affect the way the 
peaks are formed. There is also possibility for applying altogether different eluent for 
this method. In previous work a 10mM ammonium formate + 0.3% formic acid eluent 
(Ishiduka, 2013) was used in a LC/MS method to measure SMZ, AMX, OTC and TYL 
from a single injection using multiple channels. 
 
The method of preparing the stock solution needs critical approach. While using the 
MeOH solution had its advantages, it is possible that it is unsuitable for this 
pharmaceutical due to instability of AMX in the solution. A weak acid or alkaline 
solution could be tried. 
 
Future experiments could be performed using a single buffer solution at different 
strengths (for example 50mM, 100mM, 400mM). However, there is a possibility that 
more peak distortions will occur when using a stronger diluent solution. 
 
Another interesting topic would be to identify the different peaks detected. This 
information would be beneficial in determining the cause(s) for separate peaks to appear 
in the chromatogram. 
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12 APPENDIX A 
 
Chromatogram for 200mM pH 8,5 phosphate buffer+1,5% MeOH+15ppm AMX 
injection (45min) (SIG1026833). 
 
Chromatogram for 200mM pH 8,5 ammonium buffer+1,5% MeOH+15ppm AMX 
injection (51min) (SIG1026868). 
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